Free Trial

Madrigal Pharmaceuticals (MDGL) Stock Price, News & Analysis

Madrigal Pharmaceuticals logo
$319.87 +4.41 (+1.40%)
Closing price 04:00 PM Eastern
Extended Trading
$319.50 -0.38 (-0.12%)
As of 05:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Madrigal Pharmaceuticals Stock (NASDAQ:MDGL)

Key Stats

Today's Range
$314.57
$327.59
50-Day Range
$267.56
$315.46
52-Week Range
$200.63
$377.46
Volume
316,922 shs
Average Volume
364,360 shs
Market Capitalization
$7.10 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$420.63
Consensus Rating
Moderate Buy

Company Overview

Madrigal Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
85th Percentile Overall Score

MDGL MarketRank™: 

Madrigal Pharmaceuticals scored higher than 85% of companies evaluated by MarketBeat, and ranked 160th out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Madrigal Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Madrigal Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.

  • Read more about Madrigal Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Madrigal Pharmaceuticals are expected to grow in the coming year, from ($23.47) to ($12.00) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Madrigal Pharmaceuticals is -17.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Madrigal Pharmaceuticals is -17.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Madrigal Pharmaceuticals has a P/B Ratio of 9.25. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Madrigal Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    22.78% of the float of Madrigal Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Madrigal Pharmaceuticals has a short interest ratio ("days to cover") of 11.9, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Madrigal Pharmaceuticals has recently decreased by 4.34%, indicating that investor sentiment is improving.
  • Dividend Yield

    Madrigal Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Madrigal Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    22.78% of the float of Madrigal Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Madrigal Pharmaceuticals has a short interest ratio ("days to cover") of 11.9, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Madrigal Pharmaceuticals has recently decreased by 4.34%, indicating that investor sentiment is improving.
  • News Sentiment

    Madrigal Pharmaceuticals has a news sentiment score of 1.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.01 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Madrigal Pharmaceuticals this week, compared to 8 articles on an average week.
  • Search Interest

    Only 2 people have searched for MDGL on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Madrigal Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Madrigal Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    21.50% of the stock of Madrigal Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    98.50% of the stock of Madrigal Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Madrigal Pharmaceuticals' insider trading history.
Receive MDGL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Madrigal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

MDGL Stock News Headlines

“The Best Gold Investment You’ve Never Heard Of”
Gold may be surging past $3,500 — but one rare class of stocks is leaving bullion in the dust. Gold royalties have outpaced physical gold by 150X and even outperformed Buffett’s track record by 18,200%. These companies don’t mine gold… they get paid in gold. Now, one analyst is revealing his top 3 picks.
See More Headlines

MDGL Stock Analysis - Frequently Asked Questions

Madrigal Pharmaceuticals' stock was trading at $308.57 on January 1st, 2025. Since then, MDGL shares have increased by 3.7% and is now trading at $319.87.

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) issued its earnings results on Thursday, May, 1st. The biopharmaceutical company reported ($3.32) earnings per share for the quarter, beating the consensus estimate of ($3.62) by $0.30. The biopharmaceutical company earned $137.25 million during the quarter, compared to analysts' expectations of $112.79 million. Madrigal Pharmaceuticals had a negative trailing twelve-month return on equity of 50.54% and a negative net margin of 123.38%.
Read the conference call transcript
.

Madrigal Pharmaceuticals' top institutional shareholders include Wealth Enhancement Advisory Services LLC and Park Avenue Securities LLC. Insiders that own company stock include Bros Advisors Lp Baker, Rebecca Taub, Paul A Friedman, William John Sibold, Brian Joseph Lynch, Richard S Levy, Fred B Craves, Carole Huntsman, Shannon T Kelley, Robert E Waltermire, James M Daly and Remy Sukhija.
View institutional ownership trends
.

Shares of MDGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Madrigal Pharmaceuticals investors own include American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), DiamondRock Hospitality (DRH), The RMR Group (RMR), Humana (HUM) and AU Optronics (AUOTY).

Company Calendar

Last Earnings
5/01/2025
Today
7/14/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:MDGL
CIK
1157601
Employees
90
Year Founded
2011

Price Target and Rating

High Price Target
$469.00
Low Price Target
$350.00
Potential Upside/Downside
+31.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.89
Research Coverage
9 Analysts

Profitability

EPS (Trailing Twelve Months)
($18.05)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$465.89 million
Net Margins
-123.38%
Pretax Margin
-123.38%
Return on Equity
-50.54%
Return on Assets
-37.19%

Debt

Debt-to-Equity Ratio
0.17
Current Ratio
5.91
Quick Ratio
5.58

Sales & Book Value

Annual Sales
$180.13 million
Price / Sales
39.30
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$34.59 per share
Price / Book
9.22

Miscellaneous

Outstanding Shares
22,200,000
Free Float
17,429,000
Market Cap
$7.08 billion
Optionable
Optionable
Beta
-1.05

Social Links

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:MDGL) was last updated on 7/14/2025 by MarketBeat.com Staff
From Our Partners